Article Contents ::
Details About Generic Salt :: Gemfibrozil
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Fluid , Electrolyte Preparations
| 4F. ANTI-HYPERLIPIDEMICS in 4. CARDIOVASCULAR SYSTEM |
| GEMFIBROZIL |
| LIPID REGULATOR (FIBRIC ACID DERIVATIVE) | ANTI-HYPERLIPIDEMIC |
| PK: A: Well absorbed M: Hepatic E: Urine |
|
Indications & Dose: HYPERLIPIDEMIA PO Adult 600mg BID(type IIa, IIb, III, IV, V) |
| Contra: Hypersensitivity, hepatic dysfunction, severe renal dysfunction, primary biliary cirrhosis, pre-existing gallbladder disease, concurrent use with repaglinide, concurrent use of statins in patients with risk of myopathy, hypoalbuminemic states
Precautions: Renal impairment ADR: Serious: Atrial fibrillation, nephrotoxicity, hepatic dysfunction, angioedema, hypokalemia, myopathy, painful extremities, Raynaud’s phenomenon, rhabdomyolysis, myalgia, blood disorders, increased creatine phosphokinase, Others: myasthenia, somnolence, synovitis, paresthesia, peripheral neuritis, pruritus, decreased libido, arthralgia, bone marrow hypoplasia, depression, dermatitis, dermatomyositis, polymyositis, exfoliative dermatitis, Dyspepsia, fatigue, vertigo, eczema, rash, nausea, vomiting DDI: Serious Colchicine causes rhabdomyolysis/neuromyopathy, Ezetimibe increases cholesterol excretion into the bile (risk of gallstone formation), Statins increases the risk of rhabdomyolysis, Rosiglitazone/Pioglitazone plasma levels are significantly increased, Colestipol reduces drug absorption Diet: 30 min before food Monitor: Serum cholesterol, LFT, CBC |
